
From Basel: TOLREMO Therapeutics is working on cancer resistance - the company believes is targeting CBP/p300 just stared phase 1 data at World Lung
BiotechTV - News
00:00
Fundraising and Broader Development Opportunities
Stefanie Fluckiger-Mangual discusses active fundraising and growing strategic interest in solid tumors and multiple myeloma.
Play episode from 06:52
Transcript


